Department of Community Medicine

Permanent URI for this collectionhttp://10.0.2.71:4000/handle/123456789/391

Browse

End date: 2026Subject: search.filters.subject.India

Search Results

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Prevalence and patterns of workplace violence against doctors of North India: a cross-sectional study
    (Frontiers, 2026-05-04) Vyas, Shaili; Singh, Abhinav et al.
    Background: Workplace violence (WPV) against physicians represents an esca lating global concern, with significant implications for India. This phenomenon substantially undermines the mental health, professional morale, and clinical performance of healthcare providers. A comprehensive understanding of the prevalence, patterns, and contextual factors associated with WPV is essential to develop evidence-based prevention and mitigation strategies. Methods: A cross-sectional study was conducted with 200 physicians (100 employed at a tertiary care teaching hospital and 100 in private healthcare settings) in Dehradun, Uttarakhand, North India. Data were collected using a pretested, self-administered questionnaire assessing experiences of workplace violence, contributing factors, physicians’ perceptions, and recommended pre ventive measures. Both descriptive and inferential statistical analyses were per formed using SPSS version 23. Results: Workplace violence was reported by 75% of the respondents (95% confidence interval [CI]: 68.9–81.0%), with verbal abuse representing the most prevalent form (59.33%; 95% CI: 51.4–67.1%). Violence occurred more frequently among male physicians, particularly in private healthcare settings and surgical specialties. A majority of incidents occurred during junior residency and were perpetrated by patients’ relatives (68%) or organized groups (mobs). Notably, only 18% of cases were formally reported by police authorities. Conclusion: Workplace violence was highly prevalent among physicians in Uttarakhand, with verbal abuse and mob-related incidents constituting the pre dominant manifestations. Urgent interventions, including enhanced security measures, structured physician-patient communication programs, and stringent legal enforcement, are necessary to establish a safer and more supportive work ing environment for healthcare professionals.
  • No Thumbnail Available
    Item
    A Scoping Review to Evaluate Different Treatments Used in Advanced Nonsmall‑cell Lung Cancer in India
    (Wolters Kluwer, 2026-04-18) Semwal, Jayanti; Juyal, Ruchi et al.
    Nonsmall‑cell lung cancer (NSCLC) accounts for nearly 85% of all lung cancers and represents a major global health burden. In India, treatment strategies must be optimized through a customized approach that considers genetic and environmental differences. Objectives: To provide evidence from Indian RCTs with valuable insights into effective and cost effective treatment options. Materials and Methods: This review, conducted according to the Cochrane Handbook guidelines, identified 179,960 studies across databases—PubMed (26,383), Google Scholar (17,100), ScienceDirect/Embase (136,458), and the Clinical Trials Registry of India (19). Results: After screening, 11 primary studies involving 3,470 patients were included. Treatment regimens studied included platinum‑based chemotherapy (carboplatin and cisplatin), taxanes (paclitaxel and docetaxel), epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs), and combination therapies. Carboplatin and cisplatin were the most frequently used agents; gefitinib plus cisplatin showed better efficacy in EGFR‑mutated patients; pemetrexed plus carboplatin was more tolerable than paclitaxel plus carboplatin; and chemoimmunotherapy demonstrated superior survival outcomes compared to chemotherapy alone. Targeted therapies such as EGFR TKIs were equally effective with fewer toxicities. Conclusion: In conclusion, platinum‑based chemotherapy remains the mainstay of NSCLC treatment, but patient tolerance, mutational status, and toxicity profiles must be carefully considered. Chemoimmunotherapy and EGFR TKIs are promising alternatives with improved results, while personalized treatment approaches and novel drug combinations should be the focus of future research.